{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:57:01Z","timestamp":1794934621643,"version":"4.9.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Although many individual cases and small series of toxic erythema of chemotherapy (TEC) have been described, the full spectrum of findings is not well understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To provide a comprehensive review of the clinical and histopathologic features of TEC with an emphasis on novel histopathologic findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched our electronic medical record for \u201ctoxic erythema of chemotherapy\u201d or \u201cneutrophilic eccrine hidradenitis.\u201d Fifty-six cases meeting clinical and histopathologic criteria were identified. The electronic medical record and accompanying hematoxylin and eosin\u2013stained slides were retrospectively reviewed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The clinical findings were heterogeneous but included classic presentations such as intertriginous eruptions (34%) and acral erythema (25%). The most common histopathologic features were apoptotic keratinocytes (95%), basal vacuolar change (91%), and epithelial dysmaturation (79%). Eccrine squamous syringometaplasia was seen in over half of the cases (33\/56; 59%), whereas neutrophilic eccrine hidradenitis was uncommon (16%). Interestingly, many cases showed prominent interstitial histiocytes (55%). Other novel findings included irregular orthohyperkeratosis (23%), irregular epidermal hyperplasia (14%), and acantholysis (9%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Limitations:<\/jats:title>\n            <jats:p>As a retrospective study, it is subject to information bias.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This is the largest reported series of TEC. In addition to confirming previously reported features, we identify novel histopathologic findings to add to the spectrum of TEC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dad.0000000000002450","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T15:01:15Z","timestamp":1703257275000},"page":"337-345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Clinical and Histopathologic Spectrum of Toxic Erythema of Chemotherapy: A Series of 56 Cases From a Single Institution"],"prefix":"10.1097","volume":"46","author":[{"given":"Daniel W.","family":"Cole","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler D.","family":"Menge","sequence":"additional","affiliation":[{"name":"Dermatologists Department of Dermatology, VA Ann Arbor Healthcare System, Ann Arbor, MI;"},{"name":"Staff Dermatopathologist, CTA Pathology, Ann Arbor, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Lowe","sequence":"additional","affiliation":[{"name":"Dermatologists Department of Dermatology and Department of Pathology, University of Michigan, Ann Arbor, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May P.","family":"Chan","sequence":"additional","affiliation":[{"name":"Dermatologists Department of Dermatology and Department of Pathology, University of Michigan, Ann Arbor, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Bresler","sequence":"additional","affiliation":[{"name":"Dermatologists Department of Dermatology and Department of Pathology, University of Michigan, Ann Arbor, MI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"R1-20250616","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamadermatol.2015.4905","article-title":"Unilateral axillary toxic erythema of chemotherapy in a patient with previous axillary lymph node dissection: implications for pathophysiology and therapy","volume":"152","author":"Yeager","year":"2016","journal-title":"JAMA Dermatol."},{"key":"R3-20250616","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archderm.1985.01660010106031","article-title":"Distinctive acral erythema occurring during therapy for severe myelogenous leukemia","volume":"121","author":"Levine","year":"1985","journal-title":"Arch Dermatol."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0277-5379(90)90102-Y","article-title":"Erythema and swelling of ears after treatment with cytarabine for leukemia","volume":"26","author":"Krulder","year":"1990","journal-title":"Eur J Cancer"},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bmt.2012.218","article-title":"Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant","volume":"48","author":"Parker","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","article-title":"Supporting information retrieval from electronic health records: a report of University of Michigan's nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE)","volume":"55","author":"Hanauer","year":"2015","journal-title":"J Biomed Inform."},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hemonc.2018.09.001","article-title":"Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation","volume":"12","author":"Hunjan","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clindermatol.2015.04.008","article-title":"Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses","volume":"33","author":"Wolf","year":"2015","journal-title":"Clin Dermatol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann Oncol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archderm.1997.03890430123017","article-title":"Antineoplastic chemotherapy, sweat, and the skin","volume":"133","author":"Horn","year":"1997","journal-title":"Arch Dermatol."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00280-014-2504-y","article-title":"Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia","volume":"74","author":"Zhang","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaad.2021.01.096","article-title":"Liposomal cytarabine and daunorubicin (CPX-351\/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients","volume":"86","author":"Stoll","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1203475416644831","article-title":"Flagellate pattern of toxic erythema of chemotherapy due to doxorubicin: a case report","volume":"20","author":"Vadeboncoeur","year":"2016","journal-title":"J Cutan Med Surg."},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0046-8177(83)80239-1","article-title":"The mononuclear phagocytic system: a review","volume":"14","author":"Lasser","year":"1983","journal-title":"Hum Pathol."},{"key":"R16-20250616","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2013.10.004","article-title":"Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin","volume":"39","author":"Tamoutounour","year":"2013","journal-title":"Immunity"},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.det.2015.03.015","article-title":"Granulomatous drug eruptions","volume":"33","author":"Dodiuk-Gad","year":"2015","journal-title":"Dermatol Clin."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1365-4632.2004.02440.x","article-title":"Eccrine squamous syringometaplasia mimicking a herpetic infection","volume":"45","author":"Alonso","year":"2006","journal-title":"Int J Dermatol."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.det.2019.05.014","article-title":"Review of graft-versus-host disease","volume":"37","author":"Ramachandran","year":"2019","journal-title":"Dermatol Clin."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-017-0306-9","article-title":"Cutaneous graft-versus-host disease: diagnosis and treatment","volume":"19","author":"Strong Rodrigues","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982","volume":"256","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"R23-20250616","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/DAD.0b013e3181722ef4","article-title":"Pattern analysis of drug-induced skin diseases","volume":"30","author":"Justiniano","year":"2008","journal-title":"Am J Dermatopathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:00:33Z","timestamp":1750096833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000002450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000002450","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,13]]}}}